id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-0371-0006,FDA,FDA-2025-E-0371,Determination of Regulatory Review Period for Purposes of Patent Extension; REVUFORJ,Notice,Determinations,2026-02-26T05:00:00Z,2026,2,2026-02-26T05:00:00Z,2026-04-28T03:59:59Z,2026-02-26T20:46:51Z,2026-03847,1,0,09000064b91dec08
FDA-2025-E-0371-0005,FDA,FDA-2025-E-0371,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-12-03T05:00:00Z,2025,12,2025-12-03T05:00:00Z,,2025-12-03T18:06:05Z,,0,0,09000064b90aa4b4
FDA-2025-E-0371-0004,FDA,FDA-2025-E-0371,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-11-05T05:00:00Z,2025,11,2025-11-05T05:00:00Z,,2025-11-05T22:28:43Z,,0,0,09000064b906967a
FDA-2025-E-0371-0003,FDA,FDA-2025-E-0371,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-09-26T04:00:00Z,2025,9,2025-09-26T04:00:00Z,,2025-11-05T18:04:53Z,,0,0,09000064b8fe0d55
FDA-2025-E-0371-0001,FDA,FDA-2025-E-0371,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-02-04T05:00:00Z,2025,2,2025-02-04T05:00:00Z,,2025-02-04T18:34:59Z,,0,0,090000648691b89c
FDA-2025-E-0371-0002,FDA,FDA-2025-E-0371,Patent Extension Application from Cooley LLP (on behalf of Vitae Pharmaceuticals LLC),Other,Application,2025-02-04T05:00:00Z,2025,2,2025-02-04T05:00:00Z,,2025-02-04T18:35:14Z,,0,0,090000648691b8bc